Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS

Launched by LITHUANIAN UNIVERSITY OF HEALTH SCIENCES · Feb 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the Lithuanian version of three important scales used to assess symptoms in people with schizophrenia: the Brief Negative Symptoms Scale, the Calgary Depression Scale for Schizophrenia, and the Schizophrenia Cognition Rating Scale. The goal is to see how well these Lithuanian versions work compared to other established tests. By doing this, researchers hope to ensure that the tools used to evaluate negative symptoms, depression, and cognitive issues in schizophrenia are accurate and reliable for Lithuanian patients.

To participate in this study, individuals must be between the ages of 18 and 65 and have a diagnosis of schizophrenia as defined by specific medical guidelines. Participants will need to sign a consent form to take part in the trial. If you join the study, you can expect to complete a series of questionnaires and assessments that will help researchers understand your symptoms better. It’s important to note that people with certain other mental health conditions or those under 18 or over 65 cannot participate. This research is currently recruiting participants, and it aims to improve the way we assess and treat schizophrenia in Lithuania.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age 18 - 65 years old;
• • Diagnosis of F20, F25 or F21 according to ICD-10;
• • Signed informed consent form.
• Exclusion Criteria:
• • Age younger than 18 or older than 65 years old;
• • Did not sign the informed consent form;
• • Legally inactive person
• • Patients with a comorbid or primary diagnosis of mental retardation according to ICD-10 (F70 - F79);
• • Patients with a comorbid or primary diagnosis of mental and behavioural disorders due to psychoactive substance use (F10 - F19)
• • Patients with a comorbid of primary diagnosis of organic, including symptomatic, mental disorders (F00 - F09)